Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.24.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Jun. 30, 2023
Current assets:    
Cash and cash equivalents $ 12,504 $ 16,036
Investments in marketable debt securities 80,094 85,860
Prepaid expenses and other 3,487 3,014
Total current assets 96,085 104,910
Long-term assets:    
Investments in marketable debt securities 3,352 16,470
Right-of-use assets 2,130 2,054
Property and equipment, net 119 139
Deposits and other 464 148
Total assets 102,150 123,721
Current liabilities:    
Accounts payable 3,593 3,269
Accrued liabilities:    
Accrued clinical and other 1,394 507
Compensation and benefits 2,483 883
Current portion of operating lease liabilities 538 541
Total current liabilities 8,008 5,200
Long term liabilities:    
Operating lease liabilities, net of current portion 1,975 1,937
Embedded derivative liability 439 412
Total liabilities 10,422 7,549
Commitments and contingencies (Notes 5, 9 and 10)
Shareholders' equity:    
Preferred stock, $0.001 par value; 400 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value; 100,000 shares authorized; issued and outstanding 39,625 and 36,827 shares as of December 31, 2023 and June 30, 2023, respectively 40 37
Additional paid-in capital 381,154 377,471
Accumulated other comprehensive loss (48) (351)
Accumulated deficit (289,418) (260,985)
Total shareholders' equity 91,728 116,172
Total liabilities and shareholders' equity $ 102,150 $ 123,721